MktsMarkets

ARS Pharmaceuticals, Inc.
NASDAQ: SPRYKey statistics
SPRY News
Stories mentioning SPRY from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 22,681 | 28,087 | 32,501 | 15,717 | 7,973 | 86,581 | 2,068 | 500.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 4,336 | 3,443 | 2,751 | 4,035 | 2,952 | 3,027 | 4,423 | 6,896 |
| Sales General & Admin | 72,204 | 59,955 | 74,751 | 54,312 | 41,104 | 35,492 | 19,281 | 8,944 |
| Total Operating Expenses | 82,826 | 69,552 | 85,693 | 63,331 | 45,150 | 39,384 | 23,816 | 15,840 |
| Operating Income (Loss) | (60,145) | (41,465) | (53,192) | (47,614) | (37,177) | 47,197 | (21,748) | (15,340) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (473.00) | 61.00 | 2,041 | 2,731 | 3,237 | 3,025 | 2,620 | 2,824 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (60,618) | (41,324) | (51,151) | (44,883) | (33,940) | 49,934 | (19,128) | (12,516) |
| Earnings Per Share (Basic) | (0.61) | (0.42) | (0.52) | (0.46) | (0.35) | 0.52 | (0.20) | (0.13) |
| Earnings Per Share (Diluted) | (0.61) | (0.42) | (0.52) | (0.46) | (0.35) | 0.49 | (0.20) | (0.13) |
| Weighted Average Shares Outstanding (Basic) | 99,296 | 98,566 | 98,808 | 98,362 | 98,061 | 96,937 | 97,032 | 96,828 |
| Weighted Average Shares Outstanding (Diluted) | 99,296 | 98,566 | 98,808 | 98,362 | 98,061 | 102,391 | 97,032 | 96,828 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About SPRY
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a stock listed on the Nasdaq Stock Market under the ticker symbol SPRY. It last traded at $2.83 (Nov 9, 2026, 9:59 AM ET), up 1.4% on the day. That gives ARS Pharmaceuticals a market capitalisation of $280.5M.
Over the past 52 weeks SPRY has traded between $2.44 and $13.15.
Revenue for the quarter ended Mar 31, 2026 was $22.7M; a net loss of $60.6M. Revenue was up 184% from $8.0M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $22.7M | -$60.6M | -267.3% |
| Dec 31, 2025 | $28.1M | -$41.3M | -147.1% |
| Sep 30, 2025 | $32.5M | -$51.2M | -157.4% |
| Jun 30, 2025 | $15.7M | -$44.9M | -285.6% |
From ARS Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…